Olympics an added incentive as Japan adds to vaccine orders for Pfizer and BioNTech

31 July 2020

Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BIIB) have received a third major order in a month for their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval.

Following the orders from the UK and US governments, the Ministry of Health, Labor and Welfare (MHLW) in Japan has now come to an agreement with the companies for the supply of 120 million doses.

Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses. In the US government deal, the price agreed was $19.50 per dose. This suggests that the value of the Japanese arrangement is likely to be in excess of $2 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK